Over the last 7 days, the Australian market has remained flat, but it has risen by 14% over the past year, with earnings expected to grow by 12% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to offer potential value and growth opportunities when backed by strong financials. In this article, we explore several penny stocks that stand out for their financial strength and potential long-term growth.
Top 10 Penny Stocks In Australia
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| LaserBond (ASX:LBL) |
A$0.55 |
A$65.22M |
★★★★★★ |
| Regal Funds Management (ASX:RPL) |
A$2.57 |
A$945.09M |
★★★★★★ |
| Praemium (ASX:PPS) |
A$0.74 |
A$360.73M |
★★★★★★ |
| Ora Banda Mining (ASX:OBM) |
A$1.56 |
A$3.01B |
★★★★★★ |
| Australian Ethical Investment (ASX:AEF) |
A$4.83 |
A$549.8M |
★★★★★★ |
| EDU Holdings (ASX:EDU) |
A$0.85 |
A$105.52M |
★★★★★★ |
| Integrated Research (ASX:IRI) |
A$0.305 |
A$55.08M |
★★★★★★ |
| CTI Logistics (ASX:CLX) |
A$1.775 |
A$143.6M |
★★★★☆☆ |
| Cogstate (ASX:CGS) |
A$2.44 |
A$416.84M |
★★★★★★ |
| GWA Group (ASX:GWA) |
A$2.05 |
A$532.46M |
★★★★★☆ |
Click here to see the full list of 388 stocks from our ASX Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Australian Clinical Labs
Simply Wall St Financial Health Rating:★★★★☆☆
Overview:Australian Clinical Labs Limited offers pathology diagnostic services in Australia and has a market cap of A$390.15 million.
Operations:The company's revenue is derived from its Pathology/Clinical Laboratory Services segment, which generated A$737.89 million.
Market Cap:A$390.15M
Australian Clinical Labs Limited (ACL) presents a mixed picture for penny stock investors. With a market cap of A$390.15 million, ACL's revenue from pathology services reached A$737.89 million, yet recent earnings have declined by 33.8% annually over five years and net profit margins fell to 3.6%. Despite trading well below its estimated fair value and having satisfactory debt levels with high-quality earnings, the company's dividend is not fully covered by earnings and short-term liabilities exceed short-term assets. Recent board changes and inclusion in the S&P/ASX Emerging Companies Index highlight ongoing strategic shifts within the company.
Berkeley Energia
Simply Wall St Financial Health Rating:★★★★★★
Overview:Berkeley Energia Limited is involved in the exploration and development of mineral properties in Spain, with a market cap of A$191.91 million.
Operations:Currently, there are no reported revenue segments for the company.
Market Cap:A$191.91M
Berkeley Energia, with a market cap of A$191.91 million, is pre-revenue and focused on mineral exploration in Spain. The company has a seasoned management team and board, with an average tenure of over 10 years. Despite being debt-free and having sufficient cash runway for more than three years, Berkeley reported a net loss of A$3.45 million for the recent half-year period. Ongoing arbitration against Spain over the Salamanca project could impact future operations. Recent metallurgical tests at its Conchas project show promising lithium and rubidium recovery rates, indicating potential growth avenues if resource estimation progresses favorably.
EMVision Medical Devices
Simply Wall St Financial Health Rating:★★★★★☆
Overview:EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring in Australia, with a market cap of A$164.50 million.
Operations:The company generates revenue of A$5.43 million from its research and development activities in medical device technology.
Market Cap:A$164.5M
EMVision Medical Devices, with a market cap of A$164.50 million, is pre-revenue and focused on neurodiagnostic technology for stroke diagnosis. Despite being unprofitable, the company has a robust cash position exceeding its total debt and short-term liabilities. It reported a net loss of A$3.97 million for the recent half-year period but shows potential with revenue growth forecasted at 17.89% annually despite declining earnings expectations over the next three years. The management team is experienced, and EMVision's assets provide more than a year's cash runway based on current free cash flow trends, indicating financial resilience amidst ongoing challenges.
Make It Happen
-
Click this link to deep-dive into the 388 companies within our ASX Penny Stocks screener.
-
Ready To Venture Into Other Investment Styles? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:ACL ASX:BKY and ASX:EMV.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
